Trastuzumab News and Research

RSS

Breast cancer survivors could avoid lifelong heart medication, research suggests

Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers and most won't need to continue treatment long-term, according to a study funded by the British Heart Foundation and presented at the European Society of Cardiology Congress in Munich.

30 Aug 2026

Biosimilars reduce financial burden for cancer patients and insurers

Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care.

27 Aug 2026

FDA approves new therapy for double-positive metastatic breast cancer

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with "double-positive" metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.

6 Jul 2026

FDA approves palbociclib combination for advanced HR-positive HER2-positive breast cancer

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment.

24 Jun 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

APOLLO AI learns from 25 billion medical events to predict future disease

APOLLO is a multimodal temporal foundation model trained on 25.2 billion medical events from 7.2 million patients across 33 years of Mass General Brigham records, integrating 28 medical modalities into unified “virtual patient representations.” Across 322 downstream tasks, the model showed strong performance in disease prediction, treatment-response stratification, hospital operations, and patient retrieval, supporting the idea of more computable, data-driven medicine.

23 Apr 2026

Combination therapy shows promise for leptomeningeal metastasis in breast cancer

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

18 Mar 2026

New biomarkers for targeted gastric therapy

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity compared with earlier agents, most patients either fail to respond initially or eventually develop resistance.

26 Feb 2026

Harnessing AI to optimize the development of new protein manufacturing processes

Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds.

17 Feb 2026

HER2 gastric cancer: Unraveling resistance at single-cell resolution

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies.

16 Feb 2026

Lower hinge of immunoglobulin G acts as a critical immune control hub

The lower hinge of immunoglobulin G (IgG), an overlooked part of the antibody, acts as a structural and functional control hub, according to a study by researchers at Science Tokyo.

31 Jan 2026

Scientists engineer AbLecs to overcome cancer's immune evasion tactics

Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more patients.

16 Dec 2025

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Global report reveals a decade of uneven progress in advanced breast cancer care

The ABC Global Alliance today launched the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025 - a landmark global assessment revealing a decade of remarkable scientific progress that has transformed ABC care for some patients in some countries, while many others around the world have yet to benefit.

5 Nov 2025

UCLA experts call for individualized heart monitoring in breast cancer survivors

As breast cancer survival rates continue to climb - 4.3 million women in the U.S. are currently living with a history of the disease and in the next 10 years that number is expected to rise by another million - heart health has become an increasingly important part of survivorship care.

4 Nov 2025

Advancements and clinical translation of intelligent nanodrugs for breast cancer treatment

A comprehensive review in "Biofunct. Mater." meticulously details the most recent advancements and clinical translation of intelligent nanodrugs for breast cancer treatment.

24 Oct 2025

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.

22 Oct 2025

New antibody drug conjugates can transform early HER2-positive breast cancer treatment

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents-antibody-drug conjugates (ADCs)-can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.

18 Oct 2025

HER2 and CD24 emerge as promising radiotheranostic targets in endometrial cancer

Two molecular targets-human epidermal growth factor 2 (HER2) and cluster of differentiation 24 (CD24)-are highly promising candidates for new nuclear diagnostics and therapeutics for endometrial cancer, according to new research published in The Journal of Nuclear Medicine.

5 Sep 2025

Lauric acid could be a key cancer-fighting compound in coconut oil

Virgin coconut oil and lauric acid show promise in inhibiting cancer cell growth and mitigating chemotherapy toxicity, paving the way for future therapies.

11 Aug 2025